Gilead Sciences: Don’t Expect Perfection
August 29, 2016 at 13:34 PM EDT
As if Gilead Sciences ( GILD ) didn't have enough to worry about with competition in hepatitis C , now the Wall Street Journal is reporting that GlaxoSmithKline ( GSK ) is attempting to upend the HIV market too. Piper Jaffray's Joshua Schimmer and team don't seem to worried: